AngieJ
May 13, 2017, 12:58am
1
Wondering if anyone here has heard of TV-45070. It’s a new pain med in development by Teva Neuroscience and Xenon. I just read an article in this month’s Wired magazine about it and it blew my mind. I did a Google search on it and came up with this from Teva - could be promisinghttp://www.tevapharm.com/news/teva_and_xenon_provide_update_on_tv_45070_phase_2b_study_in_osteoarthritis_pain_07_15.aspx
Jeff
May 14, 2017, 10:23pm
2
I hadn’t previously heard of this medication, but there are some other, more recent articles about it. Still seems like it’s unclear whether this medication will be proven effective.
N Price, R Namdari, J Neville, KJ Proctor, S Kaber, J Vest, M Fetell, R Malamut, RP Sherrington, SN Pimstone and YP Goldberg,
The Clinical journal of pain , Apr 2017
The objective was to evaluate the safety and efficacy of TV-45070 ointment, as a treatment for postherpetic neuralgia, and to explore the response in patients with the Nav1.7 R1150W gain-of-function polymorphism.This was a randomized, placebo-controlled, 2-period, 2-treatment crossover trial. Patients with postherpetic neuralgia with moderate or greater pain received TV-45070 and placebo ointments, each applied twice daily for 3 weeks. The primary efficacy measure was the difference in change in mean daily pain score from baseline compared with the last week of placebo and active treatment. Secondary endpoints included responder rate analyses and a further exploratory analysis of response in carriers of the Nav1.7 R1150W polymorphism was conducted.Seventy patients were enrolled and 54 completed the study. TV-45070 was safe and well tolerated. No statistical difference was observed between treatments for the primary endpoint. However, the proportion of patients with ≥50% reduction in mean pain scores at week 3 was greater on TV-45070 than on placebo (26.8% vs. 10.7%, P=0.0039). Similarly, a greater proportion of patients on TV-45070 had a ≥30% reduction in mean pain scores at week 3 (39.3% on TV-45070 vs. 23.2% on placebo, P=0.0784). Of note, 63% of patients with the R1150W polymorphism versus 35% of wild-type carriers had a ≥30% reduction in mean pain score on TV-45070 at week 3 (no inferential analysis performed).The 50% responder analysis suggests a subpopulation may exist with a more marked analgesic response to TV-45070.The trend toward a larger proportion of responders within Nav1.7 R1150W carriers warrants further investigation.
If it was from a company other than TEVA I would have a look see.
AngieJ
May 14, 2017, 11:48pm
4
I’ve been on Teva’s meds before. I have no qualms with them. It’s just exciting that they are at least looking into developing a pain medicine that works in this specific way. Hopefully there’s a pay off.
GEOxp
June 3, 2017, 9:21am
5
thank you a lot for the news
1 Like
Has anyone out there tried cannabis juicing for pain?
Thank you for sharing this news. I wonder if there have been any new developments with this or other medications.